HIHiromi Ito

Hiromi Ito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiromi Ito has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exploratory analysis on crosstalk between intra-tumor immunity and FGF/FGFR pathway in clear cell renal cell carcinoma.

    by Takafumi Narisawa, Sei Naito, Yoshihide Mitsuda, Rintaro Oe, Hidenori Sato, Chizuru Kobayashi, Mizuki Fukuda, Takumi Kitaoka, Yuki Miyano, Hiromi Ito, et al.

    E16525 Background: Clear cell renal cell carcinoma (ccRCC) patients classically show good response to VEGFR inhibitors; however, the biological basis by which FGFR inhibition provides tumor response was not well understood. Here, we performed an exploratory analysis of the relationship between the FGF/FGFR pathway and intra-tumor immunity to support the effectiveness of FGFR inhibitors for ccRCC. Methods: We used whole transcriptome data and immunohistochemistry with metastatic clear cell RCC specimens from patients who were treated at the Yamagata University Hospital (n = 57). FFPE samples were prepared from the primary lesions of treatment-naive metastatic ccRCC patients. FFPE was sliced by a pathologist to evaluate the immunological microenvironment. RNA extraction and immunostaining were performed at the same site. Immuno-histological quantification was performed by automatically analysis system HALO in digital whole slide imaging. Hierarchical clustering was performed, and the cohort was divided based on the profile of the FGF and immune cells. We analyzed the cancer-specific survival based on the FGF cluster classification and investigated the relationship between FGF-FGFR expression and immune cell infiltration that were evaluated histologically. Results: RNA transcriptome data showed that FGF2 and FGF7 were widely expressed in ccRCC. Hierarchical cluster analysis based on the FGF expression profile (intrinsic FGFs were excluded) revealed that metastatic ccRCC had three distinct patterns. Cluster1 showed low FGFs expression, except for FGF2 and 7, while Cluster2 and 3 expressed multiple FGFs. Survival analysis showed Cluster2and 3 had a poor cancer-specific survival rate than Cluster1 (Logrank test, p = 0.05). However, no association was detected between the FGF cluster classification and the infiltration of immune cell count in immunohistological analysis. In comparison of the expression of each FGF subfamily and the positive cells of CD4, CD8, CD68 and CD31 (Mann–Whitney U test, p < 0.05), CD4 and CD8 were higher in the cases expressing FGF20. While most FGF subfamilies have been suggested to be less associated with immune cell infiltration (excluding FGF20), further analysis among FGF receptor expression and immune signatures are ongoing. Conclusions: Our study demonstrates the possibility of intra-tumor interaction between FGF/FGFR axis and immune infiltration in ccRCC.

  • Open Access

    Comparison of analytical methods for profiling N- and O-linked glycans from cultured cell lines

    by Hiromi Ito, Hiroyuki Kaji, Akira Togayachi, Parastoo Azadi, Mayumi Ishihara, Rudolf Geyer, Christina Galuska, Hildegard Geyer, Kazuaki Kakehi, Mitsuhiro Kinoshita, et al.

    The Human Disease Glycomics/Proteome Initiative (HGPI) is an activity in the Human Proteome Organization (HUPO) supported by leading researchers from international institutes and aims at development of disease-related glycomics/glycoproteomics analysis techniques. Since 2004, the initiative has conducted three pilot studies. The first two were N- and O-glycan analyses of purified transferrin and immunoglobulin-G and assessed the most appropriate analytical approach employed at the time. This paper describes the third study, which was conducted to compare different approaches for quantitation of N- and O-linked glycans attached to proteins in crude biological samples. The preliminary analysis on cell pellets resulted in wildly varied glycan profiles, which was probably the consequence of variations in the pre-processing sample preparation methodologies. However, the reproducibility of the data was not improved dramatically in the subsequent analysis on cell lysate fractions prepared in a specified method by one lab. The study demonstrated the difficulty of carrying out a complete analysis of the glycome in crude samples by any single technology and the importance of rigorous optimization of the course of analysis from preprocessing to data interpretation. It suggests that another collaborative study employing the latest technologies in this rapidly evolving field will help to realize the requirements of carrying out the large-scale analysis of glycoproteins in complex cell samples.


  • Suspicion of primary testicular germ cell tumor regressed completely before metastasis

    by Osamu Ichiyanagi, Akira Nagaoka, Takuji Izumi, Hiromi Ito, Tomoyuki Kato, Yoshihiko Tomita

  • Open Access

    Expression System for Human Glycosyltransferases and Its Application

    by Yasunori Chiba, Hiromi Ito, Takashi Sato, Yoshie Takahashi, Yoshifumi Jigami, Hisashi Narimatsu

    糖鎖の機能解明や糖鎖構造分析のための標準品を合成するための一つの手段として,糖転移酵素の利用が考えられる.糖転移酵素は基質特異性が明確である一方,酵素自体が不安定で大量に生産することが難しいため,糖転移酵素を利用した糖鎖合成の産業的な利用は難しいと考えられてきた.一方,安価な生産のためには大量生産技術が確立している酵母等の代替宿主を用いることが期待されているが,ヒトの糖転移酵素を多量に発現させた例はあまりない.われわれは動物細胞(HEK293T細胞)とメタノール資化性酵母(Ogataea minuta)を宿主としてヒト糖転移酵素の生産法の開発と応用を検討した.既知の情報ならびに当センターで新規にクローニングした遺伝子を含め,糖鎖合成関連遺伝子をライブラリー化した.糖転移酵素のほとんどはHEK293T細胞で可溶型酵素として発現が可能であった.ビーズ上に固定した糖転移酵素を利用し,さまざまな糖鎖・糖ペプチドの合成を行った.また合成した糖鎖の一部は基板上に固定し,糖鎖チップの生産を行った.今後はさらに糖鎖の種類を増やすことで,糖鎖と結合するタンパク質の特異性をより厳密に決定に利用できると考えている.一方,酵母の発現系については,導入した糖転移酵素の半数程度しか発現が確認されなかったため,種々の条件の最適化等を検討した.その結果,従来の条件では活性がほとんどみられなかった糖転移酵素も活性が確認できるようになり,ある酵素では数百倍の生産性の向上に成功した.次に,天然からは大量調製が困難なN-型多分岐糖鎖の調製を行った.アガラクト型複合型2分岐鎖を出発材料とし,糖転移酵素を逐次作用させることにより,アシアロ型3分岐,4分岐型糖鎖の生産に成功した.今後,酵素法による糖鎖の大量調製が可能となり,糖鎖チップへの応用や糖タンパク質医薬品の原料への活用が期待できる.本研究はNEDO「糖鎖機能活用技術開発」プロジェクトにおいて実施したものである.

  • Open Access

    ATRA inhibits ceramide kinase transcription in a human neuroblastoma cell line, SH‐SY5Y cells: the role of COUP‐TFI

    by Masashi Murakami, Hiromi Ito, Kazumi Hagiwara, Kayo Yoshida, Sayaka Sobue, Masatoshi Ichihara, Akira Takagi, Tetsuhito Kojima, Kouji Tanaka, Keiko Tamiya‐Koizumi, et al.

    Ceramide is the central lipid in the sphingolipid metabolism. Ceramide kinase (CERK) and its product, ceramide 1‐phosphate, have been implicated in various cellular functions. However, the regulatory mechanism of CERK gene expression remains to be determined. Here, we examined CERK mRNA level during all‐trans retinoic acid (ATRA)‐induced differentiation of a human neuroblastoma cell line, SH‐SY5Y. ATRA reduced CERK mRNA and protein levels. Over‐expression and small interfering RNA (siRNA) of CERK revealed that CERK is inhibitory against ATRA‐induced neuronal differentiation and cell growth arrest. ATRA inhibited the transcriptional activity of 5′‐promoter of CERK. Truncation and mutation study suggests that ATRA‐responsible region was mainly located in the tandem retinoic acid responsive elements (RARE) between −40 bp and the first exon. The electrophoresis mobility shift assay revealed that ATRA produced two retarded bands, which were erased by antibody against chicken ovalbumin upstream promoter transcription factor I (COUP‐TFI), RARα, and RXRα, respectively. DNA pull‐down assay confirmed increased binding of these transcription factors to RARE. Transient expression of RAR, RXR, and COUP‐TFI and siRNA transfection of these genes revealed that COUP‐TFI inhibited CERK mRNA. Furthermore, chromatin immunoprecipitation assay showed the recruitment of co‐repressors as well as three transcription factors. These results suggest that COUP‐TFI was the ATRA‐responsive suppressive transcription factor of CERK gene transcription.


  • Conduction properties of micro-crystals of 2,5-dimethyl-N,N′-dicyanoquinonediimine metal (metal = Ag, Cu) complexes on SiO2/Si substrates

    by Hiroshi M. Yamamoto, Yoshitaka Kawasugi, Hiromi Ito, Takeo Fukunaga, Toshiaki Suzuki, Kazuhito Tsukagoshi, Reizo Kato


  • Molecular‐Weight‐Tagged Glycopeptide Library: Efficient Construction and Applications

    by Hiromi Ito, Akihiko Kameyama, Takashi Sato, Katsue Kiyohara, Yoshiaki Nakahara, Hisashi Narimatsu